Research ArticleArticle

In Vitro Investigation of Amyloid-β Hepatobiliary Disposition in Sandwich-Cultured Primary Rat Hepatocytes

Loqman A. Mohamed and Amal Kaddoumi
Drug Metabolism and Disposition October 2013, 41 (10) 1787-1796; DOI: https://doi.org/10.1124/dmd.113.052514

Abstract

Failure in amyloid-β (Aβ) systemic clearance across the liver has been suggested to play a role in Aβ brain accumulation and thus to contribute largely to the pathology of Alzheimer’s disease (AD). The purpose of this study was to characterize in vitro the transport mechanisms of Aβ40 across the liver using sandwich-cultured primary rat hepatocytes (SCHs) and to determine its biliary clearance (CLbile) and biliary excretion index (BEI%). 125I-Aβ40 BEI% was time dependent and reached steady state at 30 minutes, with an average value of 29.8% and a CLbile of 1.47 ml/min per kilogram of body weight. The role of low-density lipoprotein receptor–related protein-1 (LRP1) in mediating the basolateral uptake of 125I-Aβ40 in SCHs was assessed using receptor-associated protein (RAP, 2 µM). A significant reduction in 125I-Aβ40 BEI% and CLbile with RAP was observed, demonstrating a major contribution of LRP1 in mediating hepatic uptake of intact 125I-Aβ40 via transcytosis. Furthermore, activity studies suggested a lower role of receptor for advanced glycation end products (RAGE) in 125I-Aβ40 hepatic uptake. Verapamil (50 µM) and valspodar (20 µM) significantly reduced 125I-Aβ40 BEI%, indicating a role for P-glycoprotein (P-gp) in the biliary excretion of 125I-Aβ40 in SCHs. LRP1- and P-gp-mediated 125I-Aβ40 biliary excretion was inducible and increased BEI% by 26% after rifampicin pretreatment. In conclusion, our findings demonstrated that besides LRP1, P-gp and, to a lesser extent, RAGE are involved in 125I-Aβ40 hepatobiliary disposition and support the use of enhancement of Aβ hepatic clearance via LRP1 and P-gp induction as a novel therapeutic approach for the prevention and treatment of AD.

Introduction

Alzheimer’s disease (AD) is a complex neurodegenerative disease and the most common cause of dementia (Sagare et al., 2012). AD is characterized by specific neuropathological lesions, including progressive deposition of the intracellular neurotoxic form of the amyloid-β (Aβ) peptides Aβ40 and Aβ42 and extracellular Aβ as senile plaques throughout the brain (Makarova et al., 2004). It has been suggested that elevated levels of brain Aβ monomers result in the formation of neurotoxic Aβ oligomers, which contribute largely to the pathogenesis of this disease (Zhao et al., 2012). Aβ is produced by enzymatic cleavage, mediated by β- and γ-secretases of the transmembrane protein amyloid precursor protein (Cam and Bu, 2006). The high levels of Aβ observed in the brain of AD patients are due mainly to overproduction of Aβ or failure of its clearance from the brain (Sommer, 2002). As a peptide, Aβ40 has poor passive membrane permeability and depends on a transport system to pass through endothelial cells of the blood-brain barrier (BBB) (Banks et al., 2003). Low-density lipoprotein receptor–related protein-1 (LRP1) is the major receptor that mediates removal of Aβ across the BBB in its free form (Deane et al., 2004) or bound to chaperone molecules such as apolipoprotein E. P-glycoprotein (P-gp), expressed on the luminal side of the BBB, mediates the efflux of Aβ into the peripheral circulation (Cirrito et al., 2005; Abuznait and Kaddoumi, 2012). It has been reported that the expression of LRP1 and P-gp at the BBB is decreased and expression of the receptor of advanced glycation end product (RAGE), which influxes circulating Aβ into the brain across the BBB, is increased in AD patients, which favors Aβ accumulation inside the brain (Deane et al., 2003, 2012; Donahue et al., 2006; Sagare et al., 2007; Castellano et al., 2012). In addition to the role of Aβ transport proteins, several Aβ-degrading enzymes contribute significantly to Aβ clearance. Numerous in vitro and in vivo studies support the physiologic role of the insulin-degrading enzyme, neprilysin, endothelin-converting enzyme-1 and -2, among others, in Aβ degradation (Eckman and Eckman, 2005; Saido and Leissring, 2012). Plasma Aβ, including Aβ that is effluxed from the brain, undergoes rapid clearance mainly through the liver in its free or plasma lipoprotein-bound form (Tamaki et al., 2006; Marques et al., 2009). Recently, several studies have reported that endogenous soluble circulating low-density lipoprotein receptor-related protein (sLRP) plays an important role in the clearance of systemic Aβ “sink activity” and maintenance of Aβ brain homeostasis (Quinn et al., 1997; Sagare et al., 2007). Second, LRP normally binds 70–90% of circulating plasma Aβ and forms complexes that are unable to enter the brain across the BBB and favor its elimination mainly through the liver (Deane et al., 2008; Sagare et al., 2011); however, in AD, sLRP1 is mostly oxidized, which prevents its binding to circulating Aβ40 and causes a sharp increase in free Aβ40 plasma levels (Sagare et al., 2011).

LRP1 is expressed abundantly in the liver, mainly in hepatocytes, and is considered the major receptor that clears Aβ from the general circulation (Tamaki et al., 2006). Receptor-associated protein (RAP) has shown to inhibit Aβ40 liver uptake in rats by 48%, indicating the role of LRP1 in mediating the hepatic uptake of 125I-Aβ40 from the circulation (Tamaki et al., 2006). In another study, portal infusion of insulin increased the expression of hepatic LRP1 at the cell membrane in a time-dependent manner and induced the apparent hepatic uptake of Aβ40 in a concentration-dependent manner (Tamaki et al., 2007). Several studies have demonstrated the involvement of liver as a main pathway in the clearance of Aβ from the peripheral circulation and have shown that faulty clearance of plasma-free Aβ contributes largely to AD (Ghiso et al., 2004; Sagare et al., 2007; Sutcliffe et al., 2011). These studies, however, focused on LRP1’s contribution to the hepatic clearance of Aβ. Although LRP1 was determined to be the major pathway for Aβ systemic clearance, other mechanisms of transport in the liver that play role in Aβ hepatic clearance need further investigation. Hence, in the current study, we aimed to characterize the mechanism of Aβ40 hepatic uptake, as well as biliary excretion, and to address the role of P-gp, LRP1, and RAGE in this process using sandwich-cultured primary rat hepatocytes (SCHs), which impart the advantage of studying the vectorial transport of substrates. Since P-gp and RAGE are expressed in the brain and contribute to Aβ brain homeostasis, we hypothesized that both of these transport proteins, in addition to LRP1, mediate the hepatic uptake and biliary elimination of Aβ40.

Materials and Methods

Collagenase (type I, class I), rat-tail collagen (type I), Dulbecco’s modified Eagle’s medium (DMEM), and insulin were purchased from Invitrogen (Carlsbad, CA). Rifampicin, caffeine, 1,1,1,3,3,3-hexafluoro-2-propanol, rhodamine123 (Rh123), dexamethasone, bovine serum albumin (BSA), 10× DMEM, soybean trypsin inhibitor, and fetal bovine serum (FBS) were purchased from Sigma-Aldrich (St. Louis, MO). Synthetic monoiodinated and nonoxidized 125I-Aβ40 (human, 2200 Ci/mmol) was purchased from PerkinElmer (Boston, MA). [14C]Salicylic acid and [3H]taurocholate were obtained from American Radiolaeled Chemicals (St. Louis, MO). ITS culture supplement (10 µg/ml insulin, 10 µg/ml transferrin, 10 ng/ml selenous acid) was obtained from BD Biosciences (San Jose, CA). RAP was purchased from Oxford Biomedical Research (Oxford, MI). Valspodar was obtained from XenoTech (Lenexa, KS). The reagents and supplements required for Western blotting were purchased from Bio-Rad (Hercules, CA). For Western blot, the mouse monoclonal antibody C-219 against P-gp was obtained from Covance Research Products (Dedham, MA); mouse monoclonal antibody against light-chain LRP1 was obtained from Calbiochem (Gibbstown, NJ); mouse monoclonal antibody against RAGE, goat polyclonal antibodies against actin (C-11), and horseradish peroxidase–labeled secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Total protein measurement’s reagents with the bicinchoninic acid method were from Pierce (Rockford, IL). All other chemicals and reagents were of analytical grade and were readily available from commercial sources.

Animals

Sprague-Dawley male rats from Harlan Laboratories (Houston, TX) were used for the experiments of isolation of hepatocytes from entire liver. Rats’ age was around 2 to 3 months with an average weight between 260 and 340 g. Animals were allowed easy access to water and standard food and maintained at 22°C, 35% relative humidity and 12-hour dark/light cycle. All animal experiments were approved by and surgical procedures consistent with the policies and procedures of the Institutional Animal Care and Use Committee of the University of Louisiana at Monroe.

Isolation of Primary Rat Hepatocytes

The isolation and purification procedures of hepatocytes from animals’ livers were done under aseptic conditions. Each animal was anesthetized with an intraperitoneal injection of 0.06 g/kg of ketamine/0.012 g/kg of xylazine; then the liver portal vein was cannulated, and perfusion was started after the previously described two-step collagenase perfusion technique (Seglen, 1976). First, the liver was perfused with 450 ml of Ca2+-free Hanks’ balanced salt solution (HBSS) buffer containing 1 mM EGTA and 0.022 mg/ml heparin neutralized to pH 7.4 at a flow rate of 35 ml/min, immediately after which the liver was perfused with 350 ml of standard HBSS supplemented with 5 mM CaCl2, 100 U/ml collagenase type I, and 70 mg of soybean trypsin inhibitor at a flow rate of 30 ml/min. All solutions and tubing were maintained at 37°C and saturated with 95% O2/5% CO2. After the perfusion step, the liver was excised and put in a dish containing warm DMEM supplemented with 5% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, 4 mg/l insulin, and 1 µM dexamethasone and placed on ice to reach 4°C. The liver capsule was stripped slowly, and cells were released by gently combing the liver with a steel comb. Cells were filtered through 70-µm mesh, and hepatocytes were separated from the other liver cell population by centrifugation at 50g for 5 minutes twice, followed by centrifugation with 35% Percoll solution to remove dead cells. Hepatocytes were resuspended in serum-free medium, and viability was determined using the trypan blue method.

Preparation of Sandwich-Cultured Primary Rat Hepatocytes

All culture plates were precoated with a thin collagen layer as a matrix for the attachment of hepatocytes. Twenty-four- and six-well plates were coated with 300 and 1400 µl of 50 µg/ml collagen in 0.2 M acetic acid solution, respectively, and left to dry overnight inside the hood. Plates were then neutralized and washed twice with sterile distilled water, and then 0.5 ml/well of DMEM was added and the plates were incubated at 37°C for 2 to 3 hours to hydrate the collagen layer before seeding the cells. Hepatocytes were seeded at 0.7 × 106 cells/ml and allowed to attach for 1 to 2 hours. The medium was then aspirated to remove unattached dead cells, followed by the addition of 0.5 ml/well of fresh medium (DMEM supplemented with 5% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, 4 mg/l insulin, and 1 µM dexamethasone) and incubated for 6 hours. Medium was then replaced with serum-free medium supplemented with 1% ITS, 100 U/ml penicillin, 100 g/ml streptomycin, and 0.1 µM dexamethasone. Twenty-four hours later, the medium was removed and hepatocytes were overlaid with 0.5 ml of 0.25 mg/ml Matrigel (BD Discovery Labware, Franklin Lakes, NJ) in ice-cold medium and incubated at 37°C for 24 hours, after which medium was replaced with fresh medium each day up to day 4, when activity studies or protein extractions for Western blot were performed.

Validation of Sandwich-Cultured Primary Rat Hepatocytes Model

Light Microscopy Imaging.

To confirm the integrity of canalicular networks, phase-contrast microscopy images were taken on day 4 of SCHs using a Nikon Eclipse TS100 inverted microscope from EquipNet, Inc. (Canton, MA).

Fluorescence Microscopy Imaging.

We used 5-(and-6)-carboxy-2′,7′-dichlorofluorescein diacetate (CDFDA) as a canalicular marker in SCHs on day 4. CDFDA is passively uptaken into hepatocytes and metabolized into the fluorescent metabolite 5-(and-6)-carboxy-2′,7′-dichlorofluorescein (CDF), which is actively effluxed into the canalicular space via multidrug resistance–associated protein 2 (Liu et al., 1999b). In these experiments, a culture plate was rinsed with standard HBSS and incubated in the same buffer for 10 minutes. After aspiration of the buffer, 2 μM CDFDA dissolved in HBSS containing 5 mM CaCl2 was added to the cells and incubated for 10 minutes, followed by aspiration and washing four times with ice-cold standard HBSS. Images were then captured for accumulated CDF into canalicular spaces using inverted microscope Olympus 1x71 (Center Valley, PA) at 20× magnification.

Cumulative Uptake of [3H]Taurocholate and [14C]Salicylic Acid in SCHs as Positive and Negative Controls, Respectively.

On day 4 of SCHs, cells were washed with warm standard HBSS (i.e., containing 5 mM CaCl2) or Ca2+-free HBSS containing EDTA and then incubated in their respective buffers for 5 minutes. Subsequently, 1 µM of either [3H]taurocholate or [14C]salicylic acid was dissolved in HBSS with or without calcium and added to the cells. After 10 minutes of incubation at 37°C, the plates were placed on ice and uptake was ended by aspirating the incubation medium and washing the wells four times with ice-cold standard HBSS. Cells were lysed by adding 200 μl radioimmunoprecipitation (RIPA) buffer (25 mM Tris HCl, 150 mM NaCl, 1% NP-40, 1% sodium deoxylate, 0.1% SDS, pH 7.6) containing a 1% protease inhibitors cocktail, sonicated for 30 seconds, and incubated on ice with shaking for 2 hours. Samples were analyzed using a Wallac 1414 WinSpectral Liquid Scintillation Counter (PerkinElmer). Data were normalized to protein content in each well using a bicinchoninic acid protein assay kit with BSA as standard.

Canalicular Efflux of Rh123.

Rh123 is passively uptaken into hepatocytes, and its biliary excretion is mediated by P-gp (Annaert and Brouwer, 2005). On day 4, SCHs in six-well plates were rinsed twice in standard HBSS and incubated in the same buffer for 10 minutes. Subsequently, the buffer was aspirated and cells were preloaded with 1 µM Rh123 dissolved into standard HBSS for 30 minutes, followed by aspiration of the incubation medium and washing four times with ice-cold HBSS. Afterward, an efflux study was initiated by incubating the cells in warm HBSS with or without calcium for 30 minutes at 37°C. At the end of the incubation time, aliquots from incubation medium were measured for fluorescent intensity of Rh123 using Synergy 2 microplate reader (Biotek, Winooski, VT) with excitation and emission wavelengths of 485 and 529 nm, respectively. Data acquisition was achieved using Gene5 software (Biotek). Data were normalized to protein content in each well, and the biliary excretion index (BEI%) of Rh123 was calculated using eq. 1, as described in the Data Analysis section.

Western Blot Analysis

Hepatocytes were seeded in six-well plates and maintained up to 4 days in sandwich configuration. For induction studies with rifampicin, hepatocytes were cultured in sandwich configuration for 2 days, and then rifampicin treatment (50 µM) was initiated and added fresh each day up to day 4 of sandwich culture. Subsequently, media were removed and cells were washed twice using ice-cold HBSS, scraped, collected in 1.5-ml Eppendorf tubes and then centrifuged at 2000g for 10 minutes at 4°C. The cell pellets were then resuspended and homogenized in RIPA buffer containing 1% protease inhibitors cocktail and incubated on ice for 1 hour. The samples were then centrifuged at 15,000g for 15 minutes at 4°C. The lysate samples were stored at −80°C for subsequent Western blot analyses. Twenty-five micrograms of protein samples were loaded and resolved using 7.5% SDS-PAGE with a 5% stacking gel at 140 V for 1 hour. Proteins were transferred electrophoretically onto nitrocellulose membranes at 300 mA for 1.5 hours. After that, the membranes were blocked by incubation with 2% BSA on a rocking platform for 1 hour at room temperature, followed by incubation with the primary antibodies RAGE IgG (N-16), P-gp (C-219), LRP1 (light chain), or β-actin (C-11) at dilutions 1:125, 1:200, 1:1500, and 1:3000, respectively, in phosphate-buffered saline (PBS) containing 2% BSA and 0.05% Tween-20 overnight at 4°C. For detection of proteins, membranes were incubated with secondary anti-mouse IgG antibody for P-gp, anti-goat IgG antibody for RAGE and β-actin, or anti-rabbit IgG antibody for LRP1, all labeled with horseradish peroxidase, at 1:5000 dilution for P-gp, RAGE, and β-actin or 1:2000 dilution for LRP1 for 1 hour at room temperature. The blots were developed using a chemiluminescence detection kit (SuperSignal West Femto substrate; Thermo Scientific, Waltham, MA). Quantitative analysis of the immunoreactive bands was performed using Syngene luminescent image analyzer (Scientific Resources Southwest, Inc., Stafford, TX). Protein quantification was performed, and data were expressed as ratio of proteins to β-actin.

Immunocytochemistry of RAGE

SCHs cultured for 4 days were fixed in a 2% glutaraldehyde in PBS solution for 30 minutes at room temperature, followed by incubation with a 0.1% Triton ×100 solution for membrane permeabilization. The SCHs samples were placed in a blocking solution of 1% BSA in PBS solution for 1 hour at 37°C. The cells were first exposed to RAGE (A-9) primary mouse monoclonal antibody (Santa Cruz Biotechnology) for 2 hours at 37°C and subsequently exposed to a fluorescein isothiocyanate–conjugated goat anti-mouse secondary antibody (Santa Cruz Biotechnology) for 1 hour at room temperature. Images were acquired by Nikon Eclipse fluorescent microscope.

Time-Dependent Studies of 125I-Aβ40 Accumulation in Conventional and Sandwich-Cultured Primary Rat Hepatocytes

Time-dependent accumulation studies of 125I-Aβ40 in SCHs were performed on day 4. Cells were incubated with 0.5 ml of 0.14 nM 125I-Aβ40 prepared in standard or Ca2+-free HBSS. After incubation for 5, 15, 30, and 60 minutes, the cells were lysed and counted for radioactivity. To study the effect of calcium on the cumulative uptake of 125I-Aβ40, conventional cultured hepatocytes were prepared in a 24-well plate. In this case, hepatocytes were not overlaid with a second matrix layer; rather, they were seeded on hard collagen-coated plates to spread as monolayers. At the same time, hepatocytes were seeded on another plate and overlaid with a Matrigel layer to obtain sandwich configuration. The two plates were incubated for 2 days, when 0.5 ml of 0.14 nM 125I-Aβ40 was added to the cells, with or without calcium, and incubated for 5 and 30 minutes at 37°C. Uptake was ended by aspirating the medium and washing the cells with ice-cold standard HBSS while keeping plates on ice. Cells were lysed, and quantitative determination of intracellular 125I-Aβ40 accumulations was performed as mentioned. Degradation of 125I-Aβ40 was determined by trichloroacetic acid (TCA) precipitation assay (Shibata et al., 2000). Cells lysate samples were mixed (1:1 volume) with TCA (final concentration 10%) and centrifuged at 14,000g at 4°C for 10 minutes. Radioactivity in the supernatant was determined using Wallac 1470 Wizard Gamma Counter (PerkinElmer).

Determination of the BEI and Biliary Clearance of 125I-Aβ40

All experiments have their own control and were conducted on day 4 of sandwich culture. Twenty-four well plates were preincubated in standard or Ca2+-free HBSS for 5 minutes. Subsequently, 0.5 ml of 0.14 nM 125I-Aβ40 in standard or Ca2+-free HBSS was added to cell-culture plates and incubated for 30 minutes at 37°C. Uptake was stopped by placing plates on ice, removing the incubation medium, and washing the cells three times with ice-cold standard HBSS containing 0.2% BSA and once with standard HBSS only to remove BSA residue. Cells were then lysed by the addition of RIPA buffer containing 1% protease inhibitors cocktail, sonicated for 30 seconds, followed by gentle shaking on a rocking platform for 2 hours at 4°C. Intracellular radioactivity of 125I-Aβ40 was measured using a Wallac 1470 Wizard Gamma Counter. Data obtained were normalized to protein content. Results were also normalized to 125I-Aβ40 nonspecific Matrigel binding by subtracting 125I-Aβ40 bound to Matrigel-coated wells without cells. Nonspecific binding was less than 2%. The obtained data from the accumulation experiments of 125I-Aβ40, in the presence or absence of calcium, were used to calculate BEI using eq. 2 and the biliary clearance (CLbile) using eq. 3 described in the Data Analysis section.

Effect of Transport Proteins Inhibition on 125I-Aβ40 BEI and CLbile in SCHs

For P-gp inhibition studies, verapamil (50 μM) or valspodar (20 μM) was used; for LRP1 and RAGE inhibition, RAP (1 μM) and RAGE IgG antibody (10 µg/ml) were used, respectively. In these experiments, cells were washed with warm standard or Ca2+-free HBSS and incubated in their respective buffers for 5 minutes at 37°C. Then buffers were removed and replaced with 0.5 ml of 0.14 nM 125I-Aβ40 alone or with inhibitors and incubated for 30 minutes at 37°C. Subsequently, plates were placed on ice, and medium was removed by aspiration. Cells were washed three times with ice-cold 0.2% BSA in standard HBSS and once with standard HBSS to remove BSA residues. Cells were then lysed and used for 125I-Aβ40 quantification by gamma counter.

Effect of P-gp Induction by Rifampicin on 125I-Aβ40 BEI and CLbile in SCHs

Twenty-four–well plates of SCHs were treated with or without 50 µM rifampicin dissolved in serum-free DMEM (supplemented with 1% ITS, 100 U/ml penicillin, 100 g/ml streptomycin, and 1µM dexamethasone) for 48 hours, starting from day 2 of sandwich culture. After the end of treatment on day 4 of culture, medium was removed and replaced with freshly prepared medium and incubated for 8 hours as a washout period. Consequently, medium was removed by aspiration, and cells were rinsed gently with warm standard or Ca2+-free HBSS and incubated in their respective buffers for 5 minutes at 37°C/5% CO2. Cumulative uptake was initiated by adding 0.5 ml/well of 0.14 nM 125I-Aβ40 with or without calcium for 30 minutes at 37°C. Similarly, for the inhibition study, verapamil (50 µM) was coincubated with 0.14 nM 125I-Aβ40 for 30 minutes. At the end of the experiment, 125I-Aβ40 radioactivity was determined in the cell lysate, and BEI% and CLbile were calculated according to eqs. 2 and 3, respectively.

Data Analysis

The efflux of substrates into canalicular spaces in SCHs (i.e., BEI%) was determined by the cumulative efflux or cumulative uptake method. For Rh123, BEI was determined using the cumulative efflux method (Liu et al., 1999b), in which the cumulative efflux of Rh123 into Ca2+-free HBSS (cells + canaliculi) and standard HBSS (cells only) was determined. Their difference represents the canalicular efflux as shown in eq. 1:

Embedded Image(1)

For 125I-Aβ40, [3H]taurocholate, and [14C]salicylic acid, the canalicular efflux was determined by the cumulative uptake method (Liu et al., 1999b). In this case, uptake of a substrate prepared in calcium containing buffer by SCHs represents its accumulation into cells and canalicular lumen, whereas the uptake of this substrate prepared in calcium-free buffer represents its accumulation into cells only. The difference in readings between both treatments was used to calculate the BEI% and CLbile as shown in eqs. 2 and 3, respectively. In eq. 3, AUCmedium (area under the curve in medium) is defined as the product of the incubation time and substrate initial concentration in the incubation medium:

All biliary clearance values are reported with the unit ml/min per kilogram of body weight based on 200 mg of protein/g of liver and 40 g of liver/kg of rat body weight (Seglen, 1976).

Statistical Analysis

Unless otherwise indicated, all data were expressed as mean ± S.E.M. The experimental results were statistically analyzed for significant difference using unpaired two-tailed Student’s t test for two groups, and one-way analysis of variance, followed by the Bonferroni test for analysis of more than two groups. A P value less than 0.05 was considered statistically significant.

Results

SCH Model Validation.

The formation of canalicular networks was confirmed by light microscopy imaging. Figure 1A shows canalicular space formation as bright white spaces indicated by the small white arrow. The content of the canalicular space is sealed by the tight junctions, as shown in Fig. 1B, where the canalicular marker CDFDA was passively uptaken inside the hepatocytes and rapidly metabolized to the fluorescent CDF, which is effluxed into the canalicular space via multidrug resistance–associated protein 2, expressed on the apical side of hepatocytes, and confirms the formation of canalicular spaces (Liu et al., 1999b). Levels of P-gp, LRP1, and RAGE protein expression in SCHs cultured for 4 days were determined by Western blot analysis. P-gp, LRP1, RAGE, and β-actin protein were detected at 150, 85, 55, and 46 kDa, respectively, as shown in Fig. 2.

Fig. 1.
Fig. 1.

Phase-contrast image of SCHs cultured for 4 days with formed canalicular spaces as indicated by the white arrows (A) and fluorescence micrograph of SCHs at day 4 of culture after pretreatment with 2 µM CDFDA dissolved in standard HBSS, which was metabolized and effluxed rapidly into the canalicular spaces shown as intense green fluorescent as indicated by arrows (B). Scale bars = 10 μm.

Fig. 2.
Fig. 2.

Western blot analysis of P-gp, LRP1, and RAGE protein expression in SCHs at day 4 of culture, with or without 48-hour treatment with 50 µM rifampicin, started from day 2 of sandwich-cultured hepatocytes (A), with their corresponding densitometry analysis (B). Bars represent mean ± S.E.M. of n = 3. **P < 0.01; ***P < 0.001. M.wt., molecular weight; ns, not significant.

The activity of the sandwich culture was further tested by using the bile salt [3H]taurocholate for active transport and [14C]salicylic acid as a passive diffusion marker that is not excreted in the bile canaliculi. Consistent with other studies in the literature (Liu et al., 1999a), the BEI% of [3H]taurocholate was as high as 52.7% ± 8.2%, whereas for [14C]salicylic acid, it was approximately zero, as its cellular accumulation with or without calcium was approximately the same (Fig. 3A). The CLbile of [3H]taurocholate was also determined in SCHs on day 4 of culture and was 81.0 ± 7.7 ml/min per kilogram of body weight.

Fig. 3.
Fig. 3.

(A) Cumulative uptake of 1 µM [14C]salicylic acid ([14C]SA) and 1 µM [3H]taurocholate ([3H]TC) in SCHs at day 4 of culture. Hepatocytes were preincubated for 10 minutes in standard HBSS or Ca2+-free HBSS before cumulative uptake studies were conducted. BEI% and CLbile (ml/min per kilogram of body weight) were determined after 10 minutes of the addition of [14C]SA and [3H]TC. Each bar represents the mean ± S.E.M. for four replicates from three independent experiments. ***P < 0.001; ns, not significant between substrates cumulative uptake from standard HBSS and Ca2+-free HBSS based on unpaired Student’s t test. (B) Cumulative efflux of Rh123 into standard HBSS and Ca2+-free HBSS for 30 minutes in SCHs at day 4 of culture. Hepatocytes were preloaded with 1 µM Rh123 dissolved in standard HBSS for 30 minutes at 37°C, followed by efflux study. Bars represent mean ± S.E.M. for triplicates from two independent experiments. Unpaired student t test was used to compare between Rh123 efflux into standard and Ca2+-free HBSS. *P < 0.05.

Embedded Image(2)Embedded Image(3)

The functional activity of P-gp at the apical side of the SCHs was determined by using the specific substrate Rh123. Efflux of 1 µM Rh123 into the incubation buffer in presence or absence of calcium was performed, and the BEI% was calculated to be 19.4% ± 5.2% with a significant difference in its efflux between both incubation buffers (P < 0.05) (Fig. 3B).

Determination of 125I-Aβ40 BEI, CLbile, and Cumulative Uptake.

To determine the Aβ hepatic transport mechanisms, 125I-labeled Aβ40 was used for sensitive quantification. Bell et al. (2007) showed that 125I-labeling of Aβ40 did not alter the transport properties of 125I-Aβ40 compared with the unlabeled peptide and that the clearance rates of both peptides were identical. In addition, free Aβ40 instead of Aβ40-sLRP1 complex was investigated in the current studies to imitate mild cognitive impairment and AD conditions where, unlike in normal physiologic condition, sLRP1 is mostly present in oxidized form with negligible binding affinity to Aβ40, causing a sharp increase in free Aβ40 plasma levels (Sagare et al., 2011). Although Aβ42 is more prone to aggregation compared with Aβ40, both Aβ peptides have been implicated in the pathogenesis of AD (Hardy, 2006) and participate in the formation of senile plaques with neurotoxicity potentials (Chiang et al., 2008; Seeman and Seeman, 2011). Aβ40 and Aβ42 are substrates for P-gp and LRP1 (Shibata et al., 2000; Cirrito et al., 2005); thus, the clearance of both peptides is expected to be altered by these transport-protein modulations. In this study, Aβ40 was used in the BEI experiments for practical reasons, as it has a much faster clearance rate than does Aβ42 (Zlokovic et al., 2000; Ito et al., 2006).

To determine the optimum time (when steady state is achieved) for 125I-Aβ40 biliary excretion measurement, time-course accumulations with or without calcium were performed, and biliary excretion was determined at different time points. As shown in Fig. 4, the biliary excretion of 125I-Aβ40 was time dependent and reached steady state at 30 minutes with BEI% and CLbile values of 29.8% ± 2.3% and 1.47ml/min per kilogram, respectively. Thus, all subsequent cumulative uptake and BEI% studies were conducted at 30-minute incubation times. To evaluate the effect of calcium on the cumulative uptake of 125I-Aβ40, conventional hepatocyte culture (i.e., not in sandwich configuration) was seeded in parallel with SCHs and maintained for 48 hours at 37°C. Forty-eight hours of culture time was selected as the viability and functionality of conventionally cultured primary hepatocytes start to decline at longer times (Hewitt et al., 2007; Swift et al., 2010). As shown in Fig. 5A, the difference between 125I-Aβ40 cumulative uptake in the presence or absence of calcium in the conventional model was insignificant at 5 and 30 minutes, suggesting no effect of calcium on 125I-Aβ40 uptake; however, the difference in the cumulative uptake in SCHs, although not different at 5 minutes, was obvious and significant at 30 minutes’ incubation time, demonstrating excretion of 125I-Aβ40 into canalicular spaces that were maintained only in the presence of calcium. Using the TCA assay, the percentage of 125I-Aβ40 intracellular degradation was determined and ranged from 27% to 36% (Fig. 5A, P > 0.05). 125I-Aβ40 intracellular degradation, after 30 minutes of cumulative uptake, decreased significantly (∼17%) in SCHs at day 4 compared with 27% degradation at day 2 of sandwich culture (P < 0.05). On the other hand, the BEI% of total 125I-Aβ40 (intact + degraded) increased significantly with the length of culture, with 19.4% ± 3.6% and 27.5% ± 2.9% (P < 0.05) for SCHs at day 2 and 4, respectively (Fig. 5B).

Fig. 4.
Fig. 4.

Representative time course of 125I-Aβ40 BEI% in SCHs at day 4. Cumulative uptake of 0.14 nM 125I-Aβ40 dissolved in standard or Ca2+-free HBSS for 5, 15, 30, and 60 minutes was determined, and BEI% was calculated at each time point. Points represent the BEI% of Aβ40 for n = 4. *P < 0.05 compared with 5 and 15 minutes; ns, not significant compared with 30 minutes based on unpaired Student’s t test.

Fig. 5.
Fig. 5.

(A) Cumulative uptake of 0.14 nM 125I-Aβ40 in standard and Ca2+-free HBSS after 5 and 30 minutes of incubation in hepatocyte conventional culture (CC) and hepatocytes cultured in sandwich configuration for 2 days. (B) Cumulative uptake of 0.14 nM 125I-Aβ40 in standard and Ca2+-free HBSS in SCHs for 30 minutes at days 2 and 4 of culture. Aliquots were taken from cell lysates incubated with or without calcium, and degraded 125I-Aβ40 was determined using TCA assay. Bars represent the mean ± S.E.M (n = 4). *P < 0.05; **P < 0.01 compared with corresponding control.

Effect of Transport Proteins Inhibition on 125I-Aβ40 BEI and CLbile in SCHs.

Inhibition studies of major 125I-Aβ40 transport proteins were conducted to investigate the effect of such inhibition on 125I-Aβ40 cellular accumulation and biliary excretion. Figure 6 illustrates the effect of P-gp inhibition by verapamil or valspodar on 125I-Aβ40 biliary excretion in SCHs. Verapamil (50 µM) caused a significant reduction in 125I-Aβ40 BEI%, from 27.1% ± 4.1% to 12.4% ±1.4% (P < 0.05). The role of P-gp mediated canalicular efflux of 125I-Aβ40 was further confirmed with the selective inhibitor valspodar. Similarly, valspodar (20 μM) significantly reduced 125I-Aβ40 BEI% from 27.1% ± 4.1% to 9.6% ± 2.6% (P < 0.01).

Fig. 6.
Fig. 6.

Cumulative uptake, BEI%, and CLbile of 0.14 nM 125I-Aβ40 with or without P-gp–specific inhibitors verapamil (50 µM) and valspodar (20 µM). BEI% and CLbile values were determined at 30 minutes in SCHs on day 4 of culture. Bars represent the mean ± S.E.M. (n = 4). *P < 0.05; ***P < 0.001 for verapamil- and valspodar-treated cells; gray bars (Ca2+-free HBSS) compared with corresponding control. ns, not significant.

Furthermore, the role of LRP1 and RAGE in mediating the 125I-Aβ40 disposition in SCHs was assessed using specific inhibitors. As shown in Fig. 7, RAGE antibody (10 μg/ml) reduced the BEI% and CLbile of 125I-Aβ40 from 27.1% ± 4.6% to 20.6% ± 2.6% and from 1.5 ± 0.06 to 0.9 ± 0.09 ml/min per kilogram of body weight, respectively. Coincubation of 125I-Aβ40 with 2 µM RAP, a known chaperone molecule for LRP1 and a competitive inhibitor for Aβ, as determined previously (Shibata et al., 2000; Qosa et al., 2012), caused a significant reduction in the BEI% and CLbile of 125I-Aβ40 by approximately 2.4-fold (from 27.1% ± 4.6% to 11.2% ± 4.8%) and 2.7-fold (from 1.5 ± 0.06 to 0.5 ± 0.15 ml/min per kilogram of body weight) (P < 0.01), respectively. Both inhibitors, RAP and RAGE-IgG, showed comparable inhibition of Aβ40 cumulative uptake in the presence of calcium compared with control (Fig. 7, black bars), whereas its cumulative uptake in the absence of calcium between the three groups (Fig. 7, gray bars) was not significantly different, indicating that the effect of both inhibitors was on Aβ40 uptake from the sinusoidal side of hepatocytes. However, based on the difference in Aβ40 cumulative uptakes in the presence and absence of calcium, the CLbile of Aβ40 with LRP1 inhibitor was significantly lower than its CLbile with RAGE inhibitor (P < 0.01), suggesting the greater role of LRP1 in Aβ40 cellular uptake compared with RAGE.

Fig. 7.
Fig. 7.

Cumulative uptake, BEI%, and CLbile values of 0.14 nM 125I-Aβ40 with or without LRP1 and RAGE specific inhibitors; RAP (1 µM) and RAGE-IgG antibody (10 µg/ml), respectively. BEI% and CLbile values (milliliter per minute per kilogram of body weight) were determined at 30 minutes in SCHs on day 4 of culture. Bars represent the mean ± S.E.M. (n = 4). *P < 0.05 for RAP- and RAGE-IgG-treated groups; black bars (Ca2+-free HBSS) compared with corresponding control. ns, not significant.

On the other hand, TCA studies revealed that P-gp, LRP1, and RAGE inhibition did not alter the degradation % of Aβ40 (∼17%) demonstrating that Aβ40 degradation products are not substrates for these transport proteins.

RAGE localization in the SCHs was investigated and confirmed by immunocytochemistry. The results demonstrated RAGE distribution at the sinusoidal side of the SCHs (green fluorescence, Fig. 8) and was not detected at the bile canaliculi (white arrows, Fig. 8).

Fig. 8.
Fig. 8.

Localization by immunofluorescence of RAGE in SCHs cultured for 4 days. Hepatocyte culture was viewed with fluorescence merged with phase contrast and 4′,6-diamidino-2-phenylindole for nuclei staining. Culture labeled with specific RAGE monoclonal antibody followed by fluorescein isothiocyanate–conjugated secondary antibody showed an absence of signal at canaliculi (white arrows) and the presence of green fluorescence at the sinusoidal front. Scale bar = 10 μm.

Effect of Rifampicin Treatment on 125I-Aβ40 BEI% and CLbile in SCHs.

Rifampicin (50 µM) treatment significantly increased the expression of P-gp and LRP1 by 1.6- and 1.4-fold, respectively, but not RAGE expression (Fig. 2). These increases in expression were associated with enhanced BEI% and CLbile of 125I-Aβ40 compared with vehicle-treated cells. The BEI% and CLbile values of 125I-Aβ40 were significantly increased, from 30.2% ± 2.2% to 38.2% ± 1.3% and from 1.5 ± 0.15 to 1.8 ± 0.2 ml/min per kilogram of body weight, respectively (P < 0.05). P-gp inhibition by verapamil caused a significant decrease in the BEI in both control and in rifampicin-treated cells, with a more pronounced inhibitory effect on rifampicin-treated cells. As shown in Fig. 9, the BEI% of 125I-Aβ40 was significantly reduced, from 30.2% ± 2.2% to 17.4% ± 0.7% (P < 0.01) and from 38.2% ± 1.3% to 7.8% ± 1.1% (P < 0.001) in control and rifampicin-treated cells, respectively.

Fig. 9.
Fig. 9.

BEI% of 125I-Aβ40, with or without P-gp–specific inhibitor, verapamil (50 µM), in rifampicin (50 µM) or vehicle-treated cells. BEI% was determined at 30 minutes in SCHs, day 4 of culture. Bars represent the mean ± S.E.M. (n = 3). **P < 0.01; ***P < 0.001.

Discussion

Understanding Aβ hepatic transport mechanisms might unravel novel therapeutic targets to enhance Aβ systemic elimination through the liver and consequently reduce its burden in the brain (Sehgal et al., 2012). Whereas available studies focused primarily on the role of LRP1 in hepatocellular uptake of Aβ40, the contribution of P-gp and RAGE, transport proteins that have established functions in Aβ transport across BBB to the hepatic clearance of Aβ, is poorly understood. Thus, to characterize more fully the role of these transport proteins and their interplay in Aβ40 hepatic clearance, we used primary rat hepatocytes cultured in sandwich configuration.

SCHs were optimized and validated for formation of canalicular networks by observing the formation of canalicular spaces under light microscopy, as well as by accumulation of the fluorescent metabolite CDF (Fig. 1). Also, BEI% and CLbile measurements of [3H]taurocholate and [14C]salicylic acid, used as positive and negative controls, respectively, were in agreement with previous work (Liu et al., 1999a; Turncliff et al., 2006), and the functional activity of P-gp, determined using Rh123 as a model substrate, was consistent with previously reported results (Annaert and Brouwer, 2005).

For the first time, this in vitro model was successfully used to determine the BEI% of 125I-Aβ40. Treating SCHs with 125I-Aβ40 for 30 minutes demonstrated significantly higher accumulation of 125I-Aβ40 in HBSS containing calcium compared with calcium-free HBSS, with a BEI% of 29.8% ± 2.3%, which is considered moderate compared with [3H]taurocholate (52.7% ± 8.2%) and Rh123 (19.4% ± 5.2%) (Fig. 3). The effect of calcium on the difference in 125I-Aβ40 uptake in SCHs was rolled out by performing cumulative uptake studies of 125I-Aβ40 with or without calcium in primary hepatocytes cultured in conventional culture and was compared with SCHs. Degradation studies by TCA assay suggested biliary excreted 125I-Aβ40 was mostly intact (∼85%), which was supported by the intracellular degradation and modulation studies; however, the degradation of 125I-Aβ40 in SCHs decreased with culture time. Further studies are required to explain this observation, but this decrease could be due to reduced expression of Aβ40-degrading enzymes, such as neprilysin and insulin-degrading enzyme, with culture time, an observation that has been reported previously in SCHs with other enzymes, including cytochrome P450 (Hewitt et al., 2007), or reduced expression of another uptake mechanism coupled with Aβ40 endocytotic degradation.

Consistent with available studies in rats (Tamaki et al., 2006, 2007) and transgenic mice (Sehgal et al., 2012), our data demonstrate that basolateral LRP1 plays an important role in mediating the hepatic clearance of Aβ40 from the general circulation and were confirmed by inhibition studies. RAP significantly reduced 125I-Aβ40 BEI% and CLbile by 2.4- and 2.7-fold, respectively. Interestingly, the same concentration of RAP (2 µM) was reported to decrease the liver uptake of intravenously administered 125I-Aβ40 by 48% (∼2-fold) in rats (Tamaki et al., 2006), which is in agreement with our findings. Another interesting finding is that LRP1 inhibition did not affect 125I-Aβ40 degradation in SCHs (∼15% in the absence and presence of RAP), suggesting that LRP1 mediates transcytosis of intact 125I-Aβ40 in SCHs. Similar observations were reported previously by Pflanzner et al. (2011), who used primary mouse brain capillary endothelial cells grown on filters and showed that LRP1 mediates intact Aβ40 transport by transcytosis and plays no role in its degradation in this model.

P-gp is expressed abundantly on the canalicular side of hepatocytes, and Aβ40 is a P-gp substrate (Lam et al., 2001). P-gp at the apical side of BBB has been shown to play a substantial role in controlling Aβ levels in the brain by enhancing its removal from brain to blood and by limiting Aβ access to the brain (Cirrito et al., 2005; Kuhnke et al., 2007; Abuznait et al., 2011). To study the role of P-gp in the canalicular excretion of Aβ40, two potent P-gp inhibitors, verapamil and valspodar, were used. Verapamil inhibition of P-gp has been reported in various in vitro models, including SCHs (Annaert and Brouwer, 2005), Caco2 cells (Bansal et al., 2009), and the porcine kidney cell line (LCC-PK1) expressing human MDR1 (Sugimoto et al., 2011). Also, valspodar was demonstrated as an effective P-gp inhibitor in Madin-Darby canine kidney cells transfected with MDR1 (MDCKII-MDRI) and rat brain microcapillary endothelial cells (Sziraki et al., 2011). Both compounds inhibited P-gp efflux function and significantly reduced the BEI% of 125I-Aβ40 with more pronounced effect demonstrated by valspodar compared with verapamil with 64 and 54% reductions, respectively. The reduction in BEI% with both inhibitors can also be noticed from the significant increase in the accumulation of 125I-Aβ40 in calcium-free HBSS, from 2.0 ± 0.04 to 2.5 ± 0.2 (P < 0.01) and 2.2 ± 0.04 (P < 0.05) fmol/mg protein for valspodar and verapamil treated cells, respectively (Fig. 6). In the absence of calcium, the tight junctions are disrupted and the canalicular 125I-Aβ40 is released into the medium during incubation, which is consequently removed by washing at the end of the experiment; hence, any increase in 125I-Aβ40 accumulation inside the cells in the absence of calcium is due to the specific inhibition of canalicular efflux of 125I-Aβ40 through apical P-gp. To our knowledge, this function of canalicular P-gp in the hepatic clearance of Aβ40 is first shown by this study.

We also tested the role of RAGE in mediating 125I-Aβ40 clearance in SCHs. To our knowledge, RAGE localization in hepatocytes has not been identified. In this study, we successfully confirmed its sinusoidal localization in SCHs at day 4 by immunocytochemistry (Fig. 8). Inhibition studies with RAGE antibody showed a reduction by 24 and 36% in 125I-Aβ40 BEI% and CLbile, respectively (P < 0.05), demonstrating a significantly lesser role in mediating the hepatic clearance of 125I-Aβ40 than that of LRP1.

Collectively, these observations confirm hepatic LRP1 and P-gp as significant players in determining Aβ systemic levels and suggest that a small decline in their expression or activity could decrease Aβ systemic clearance and possibly contribute to Aβ accumulation in the brain. Considering the established role of age-associated decline in LRP1- and P-gp-mediated removal of Aβ peptides in humans (Vogelgesang et al., 2002) and rats (Silverberg et al., 2010), strategies to upregulate expression or activity of both proteins at the BBB have been investigated as a potential preventive approach (Hartz et al., 2010; Qosa et al., 2012). In vivo brain efflux index studies conducted on C57BL/6 mice treated with rifampicin or caffeine significantly enhanced Aβ40 clearance by more than 20% compared with control vehicle–treated mice (Qosa et al., 2012). Thus, in the current study, we investigated the effect of upregulation of both proteins by rifampicin on the hepatic clearance of Aβ40. Rifampicin treatment increased the expression of LRP1and P-gp, but not that of RAGE, and was reflected in 125I-Aβ40 disposition in SCHs. Biliary clearance and excretion of 125I-Aβ40 were significantly increased by rifampicin as a result of the enhanced functional activity of LRP1 at the basolateral side and P-gp at the apical side of hepatocytes. These results are consistent with our previous study in which treatment of mice with rifampicin for 3 weeks increased LRP1and P-gp expression at the BBB and was associated with enhanced clearance of 125I-Aβ40 across the BBB (Qosa et al., 2012). Interestingly, and consistent with our in vivo study findings (Qosa et al., 2012), P-gp inhibition with verapamil significantly reduced 125I-Aβ40 BEI% by 80% in rifampicin-treated cells compared with 43% in vehicle-treated cells, indicating that rifampicin induced another mechanism that plays an important role in 125I-Aβ40 clearance and was inhibited by verapamil. Further studies are in progress to explain this observation. Accordingly, similar to the BBB’s role in maintaining Aβ homeostasis in the brain, the role of hepatic clearance is very important in maintaining Aβ homeostasis in the body. As the level of LRP1 and P-gp expressions decrease with aging and in AD (Toornvliet et al., 2006; Silverberg et al., 2010), the level of Aβ is expected to increase in the general circulation as a result of insufficient systemic clearance (Mackic et al., 1998; Tamaki et al., 2006), which may allow for more Aβ influx into the brain. Our results demonstrated that modulation of LRP1 or P-gp alters Aβ40 biliary clearance and excretion, supporting their important function in regulating Aβ40 systemic levels; our findings also show that their upregulation presents a novel therapeutic approach for AD prevention and treatment. Furthermore, our findings suggest that although the hepatic disposition of Aβ40 is mediated by several transport proteins, competition with endogenous and exogenous substances that are mainly eliminated via a similar transport system in the liver might hinder Aβ hepatic clearance and contribute to the elevated levels of systemic Aβ observed in Alzheimer patients.

In summary, our data showed that, in addition to LRP1, P-gp is involved in the biliary excretion of Aβ40 in SCHs. Furthermore, the present study demonstrated that Aβ40 uptake in SCHs is mediated mainly by LRP1 and to a much lesser extent by RAGE. P-gp is involved not only in the clearance of Aβ40 across the BBB but also in its biliary excretion, and its role has been confirmed by inhibition and induction studies. Furthermore, SCHs provided a useful in vitro model to differentiate between Aβ40 sinusoidal and canalicular disposition and successfully determined its biliary excretion.

Authorship Contributions

Participated in research design: Mohamed, Kaddoumi.

Conducted experiments: Mohamed.

Performed data analysis: Mohamed.

Wrote or contributed to the writing of the manuscript: Mohamed, Kaddoumi.

Footnotes

    • Received April 18, 2013.
    • Accepted July 12, 2013.

  • This work was supported by a fellowship from the Ministry of Higher Education of the Libyan government; and the Libyan North American Scholarship Program (to L.A.M.).

  • dx.doi.org/10.1124/dmd.113.052514.

Abbreviations

Aβ
amyloid-β
AD
Alzheimer’s disease
BBB
blood-brain barrier
BEI%
biliary excretion index
BSA
bovine serum albumin
CDF
5-(and-6)-carboxy-2′,7′-dichlorofluorescein
CDFDA
5-(and-6)-carboxy-2′,7′-dichlorofluorescein diacetate
CLbile
biliary clearance
DMEM
Dulbecco’s modified Eagle’s medium
FBS
fetal bovine serum
HBSS
Hanks’ balanced salt solution
LRP
low density lipoprotein-receptor related protein
PBS
phosphate-buffered saline
P-gp
P-glycoprotein
RAGE
receptor for advanced glycation end products
RAP
receptor-associated proteins
Rh123
rhodamine 123
RIPA
radioimmunoprecipitation assay (buffer)
SCH
sandwich-cultured primary rat hepatocyte
sLRP
soluble low-density lipoprotein receptor-related protein
TCA
trichloroacetic acid

References

  1. ↵
    1. Abuznait AH,
    2. Cain C,
    3. Ingram D,
    4. Burk D, and
    5. Kaddoumi A
    (2011) Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer’s disease. J Pharm Pharmacol 63:1111–1118.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Abuznait AH and
    2. Kaddoumi A
    (2012) Role of ABC transporters in the pathogenesis of Alzheimer’s disease. ACS Chem Neurosci 3:820–831.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Annaert PP and
    2. Brouwer KL
    (2005) Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab Dispos 33:388–394.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Banks WA,
    2. Robinson SM,
    3. Verma S, and
    4. Morley JE
    (2003) Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer’s disease. Neuroscience 121:487–492.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bansal T,
    2. Mishra G,
    3. Jaggi M,
    4. Khar RK, and
    5. Talegaonkar S
    (2009) Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci 36:580–590.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bell RD,
    2. Sagare AP,
    3. Friedman AE,
    4. Bedi GS,
    5. Holtzman DM,
    6. Deane R, and
    7. Zlokovic BV
    (2007) Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27:909–918.
    OpenUrlPubMed
  7. ↵
    1. Cam JA and
    2. Bu G
    (2006) Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family (Abstract). Mol Neurodegener 1:8.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Castellano JM,
    2. Deane R,
    3. Gottesdiener AJ,
    4. Verghese PB,
    5. Stewart FR,
    6. West T,
    7. Paoletti AC,
    8. Kasper TR,
    9. DeMattos RB,
    10. Zlokovic B,
    11. et al.
    (2012) Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci USA 109:15502–15507.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Chiang PK,
    2. Lam MA, and
    3. Luo Y
    (2008) The many faces of amyloid beta in Alzheimer’s disease. Curr Mol Med 8:580–584.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Cirrito JR,
    2. Deane R,
    3. Fagan AM,
    4. Spinner ML,
    5. Parsadanian M,
    6. Finn MB,
    7. Jiang H,
    8. Prior JL,
    9. Sagare A,
    10. Bales KR,
    11. et al.
    (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115:3285–3290.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Deane R,
    2. Du Yan S,
    3. Submamaryan RK,
    4. LaRue B,
    5. Jovanovic S,
    6. Hogg E,
    7. Welch D,
    8. Manness L,
    9. Lin C,
    10. Yu J,
    11. et al.
    (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907–913.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Deane R,
    2. Sagare A, and
    3. Zlokovic BV
    (2008) The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer’s disease. Curr Pharm Des 14:1601–1605.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Deane R,
    2. Singh I,
    3. Sagare AP,
    4. Bell RD,
    5. Ross NT,
    6. LaRue B,
    7. Love R,
    8. Perry S,
    9. Paquette N,
    10. Deane RJ,
    11. et al.
    (2012) A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122:1377–1392.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Deane R,
    2. Wu Z,
    3. Sagare A,
    4. Davis J,
    5. Du Yan S,
    6. Hamm K,
    7. Xu F,
    8. Parisi M,
    9. LaRue B,
    10. Hu HW,
    11. et al.
    (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333–344.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Donahue JE,
    2. Flaherty SL,
    3. Johanson CE,
    4. Duncan JA 3rd.,
    5. Silverberg GD,
    6. Miller MC,
    7. Tavares R,
    8. Yang W,
    9. Wu Q,
    10. Sabo E,
    11. et al.
    (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol 112:405–415.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Eckman EA and
    2. Eckman CB
    (2005) Abeta-degrading enzymes: modulators of Alzheimer’s disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33:1101–1105.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Ghiso J,
    2. Shayo M,
    3. Calero M,
    4. Ng D,
    5. Tomidokoro Y,
    6. Gandy S,
    7. Rostagno A, and
    8. Frangione B
    (2004) Systemic catabolism of Alzheimer’s Abeta40 and Abeta42. J Biol Chem 279:45897–45908.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Hardy J
    (2006) A hundred years of Alzheimer’s disease research. Neuron 52:3–13.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hartz AM,
    2. Miller DS, and
    3. Bauer B
    (2010) Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer’s disease. Mol Pharmacol 77:715–723.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Hewitt NJ,
    2. Lechón MJ,
    3. Houston JB,
    4. Hallifax D,
    5. Brown HS,
    6. Maurel P,
    7. Kenna JG,
    8. Gustavsson L,
    9. Lohmann C,
    10. Skonberg C,
    11. et al.
    (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Ito S,
    2. Ohtsuki S, and
    3. Terasaki T
    (2006) Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res 56:246–252.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Kuhnke D,
    2. Jedlitschky G,
    3. Grube M,
    4. Krohn M,
    5. Jucker M,
    6. Mosyagin I,
    7. Cascorbi I,
    8. Walker LC,
    9. Kroemer HK,
    10. Warzok RW,
    11. et al.
    (2007) MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer’s amyloid-beta peptides: implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17:347–353.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Lam FC,
    2. Liu R,
    3. Lu P,
    4. Shapiro AB,
    5. Renoir JM,
    6. Sharom FJ, and
    7. Reiner PB
    (2001) Beta-amyloid efflux mediated by p-glycoprotein. J Neurochem 76:1121–1128.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Liu X,
    2. Chism JP,
    3. LeCluyse EL,
    4. Brouwer KR, and
    5. Brouwer KL
    (1999a) Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637–644.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Liu X,
    2. LeCluyse EL,
    3. Brouwer KR,
    4. Gan LS,
    5. Lemasters JJ,
    6. Stieger B,
    7. Meier PJ, and
    8. Brouwer KL
    (1999b) Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol 277:G12–G21.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Mackic JB,
    2. Weiss MH,
    3. Miao W,
    4. Kirkman E,
    5. Ghiso J,
    6. Calero M,
    7. Bading J,
    8. Frangione B, and
    9. Zlokovic BV
    (1998) Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer’s amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 70:210–215.
    OpenUrlPubMed
  27. ↵
    1. Makarova A,
    2. Williams SE, and
    3. Strickland DK
    (2004) Proteases and lipoprotein receptors in Alzheimer’s disease. Cell Biochem Biophys 41:139–178.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Marques MA,
    2. Kulstad JJ,
    3. Savard CE,
    4. Green PS,
    5. Lee SP,
    6. Craft S,
    7. Watson GS, and
    8. Cook DG
    (2009) Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system. J Alzheimers Dis 16:325–329.
    OpenUrlCrossRefPubMed
  29. ↵
    Pflanzner T, Janko MC, Andre-Dohmen B, Reuss S, Weggen S, Roebroek AJ, Kuhlmann CR, and Pietrzik CU (2011) LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol Aging 32:2321–2311.
  30. ↵
    1. Qosa H,
    2. Abuznait AH,
    3. Hill RA, and
    4. Kaddoumi A
    (2012) Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer’s disease. J Alzheimers Dis 31:151–165.
    OpenUrlPubMed
  31. ↵
    1. Quinn KA,
    2. Grimsley PG,
    3. Dai YP,
    4. Tapner M,
    5. Chesterman CN, and
    6. Owensby DA
    (1997) Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J Biol Chem 272:23946–23951.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Sagare A,
    2. Deane R,
    3. Bell RD,
    4. Johnson B,
    5. Hamm K,
    6. Pendu R,
    7. Marky A,
    8. Lenting PJ,
    9. Wu Z,
    10. Zarcone T,
    11. et al.
    (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13:1029–1031.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Sagare AP,
    2. Bell RD, and
    3. Zlokovic BV
    (2012) Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2:a011452.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Sagare AP,
    2. Deane R,
    3. Zetterberg H,
    4. Wallin A,
    5. Blennow K, and
    6. Zlokovic BV
    (2011) Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer’s disease. J Alzheimers Dis 24:25–34.
    OpenUrlPubMed
  35. ↵
    1. Saido T and
    2. Leissring MA
    (2012) Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med 2:a006379.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Seeman P and
    2. Seeman N
    (2011) Alzheimer’s disease: β-amyloid plaque formation in human brain. Synapse 65:1289–1297.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Seglen PO
    (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13:29–83.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Sehgal N,
    2. Gupta A,
    3. Valli RK,
    4. Joshi SD,
    5. Mills JT,
    6. Hamel E,
    7. Khanna P,
    8. Jain SC,
    9. Thakur SS, and
    10. Ravindranath V
    (2012) Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA 109:3510–3515.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Shibata M,
    2. Yamada S,
    3. Kumar SR,
    4. Calero M,
    5. Bading J,
    6. Frangione B,
    7. Holtzman DM,
    8. Miller CA,
    9. Strickland DK,
    10. Ghiso J,
    11. et al.
    (2000) Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489–1499.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Silverberg GD,
    2. Messier AA,
    3. Miller MC,
    4. Machan JT,
    5. Majmudar SS,
    6. Stopa EG,
    7. Donahue JE, and
    8. Johanson CE
    (2010) Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 69:1034–1043.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Sommer B
    (2002) Alzheimer’s disease and the amyloid cascade hypothesis: ten years on. Curr Opin Pharmacol 2:87–92.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Sugimoto H,
    2. Matsumoto S,
    3. Tachibana M,
    4. Niwa S,
    5. Hirabayashi H,
    6. Amano N, and
    7. Moriwaki T
    (2011) Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci 100:4013–4023.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Sutcliffe JG,
    2. Hedlund PB,
    3. Thomas EA,
    4. Bloom FE, and
    5. Hilbush BS
    (2011) Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer’s disease. J Neurosci Res 89:808–814.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Swift B,
    2. Pfeifer ND, and
    3. Brouwer KL
    (2010) Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 42:446–471.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Sziráki I,
    2. Erdo F,
    3. Beéry E,
    4. Molnár PM,
    5. Fazakas C,
    6. Wilhelm I,
    7. Makai I,
    8. Kis E,
    9. Herédi-Szabó K,
    10. Abonyi T,
    11. et al.
    (2011) Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study. J Biomol Screen 16:886–894.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Tamaki C,
    2. Ohtsuki S,
    3. Iwatsubo T,
    4. Hashimoto T,
    5. Yamada K,
    6. Yabuki C, and
    7. Terasaki T
    (2006) Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 23:1407–1416.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Tamaki C,
    2. Ohtsuki S, and
    3. Terasaki T
    (2007) Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 72:850–855.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Toornvliet R,
    2. van Berckel BN,
    3. Luurtsema G,
    4. Lubberink M,
    5. Geldof AA,
    6. Bosch TM,
    7. Oerlemans R,
    8. Lammertsma AA, and
    9. Franssen EJ
    (2006) Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 79:540–548.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Turncliff RZ,
    2. Tian X, and
    3. Brouwer KL
    (2006) Effect of culture conditions on the expression and function of Bsep, Mrp2, and Mdr1a/b in sandwich-cultured rat hepatocytes. Biochem Pharmacol 71:1520–1529.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Vogelgesang S,
    2. Cascorbi I,
    3. Schroeder E,
    4. Pahnke J,
    5. Kroemer HK,
    6. Siegmund W,
    7. Kunert-Keil C,
    8. Walker LC, and
    9. Warzok RW
    (2002) Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12:535–541.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Zhao LN,
    2. Long H,
    3. Mu Y, and
    4. Chew LY
    (2012) The Toxicity of Amyloid β Oligomers. Int J Mol Sci 13:7303–7327.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Zlokovic BV,
    2. Yamada S,
    3. Holtzman D,
    4. Ghiso J, and
    5. Frangione B
    (2000) Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med 6:718–719.
    OpenUrlCrossRefPubMed
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Aβ40 Biliary Excretion in SCHs

Loqman A. Mohamed and Amal Kaddoumi
Drug Metabolism and Disposition October 1, 2013, 41 (10) 1787-1796; DOI: https://doi.org/10.1124/dmd.113.052514
Permalink:
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section